But on the bright side, you... CSL benefits from strength across its business, acquisitions and shareholder-friendly policies. Rising costs and expenses may hurt its profitability. Key Insights ...
The homegrown drug company wants to be known as a smart manufacturer as much as for its role in helping to save lives. It marks the third and final piece of CSL’s $2bn investment in its home ...
Australia's CSL said on Wednesday it has got a contract from the U.S. Department of Health and Human Services (HHS) worth ...
Citi analyst Mathieu Chevrier maintained a Buy rating on CSL (CMXHF – Research Report) today and set a price target of A$345.00. The ...
“Accumulus Synergy is a catalyst for change. Leading with purpose and vision, Accumulus is not merely innovating but pioneering an industry paradigm shift for regulatory harmonization and digital ...
Australia’s biggest health company has a new weapon to accelerate its search to find the next blockbuster drugs in its $1bn annual research and development program. The $147.3bn company has ...
Australia’s biggest health company has a new weapon to accelerate its search to find the next blockbuster drugs in its $1bn annual research and development program. The $147.3bn company has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback